Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial

The RV144 clinical trial showed the partial efficacy of a vaccine regimen with an estimated vaccine efficacy (VE) of 31% for protecting low-risk Thai volunteers against acquisition of HIV-1. The impact of vaccine-induced immune responses can be investigated through sieve analysis of HIV-1 breakthrough infections (infected vaccine and placebo recipients). A V1/V2-targeted comparison of the genomes of HIV-1 breakthrough viruses identified two V2 amino acid sites that differed between the vaccine and placebo groups. Here we extended the V1/V2 analysis to the entire HIV-1 genome using an array of methods based on individual sites, k-mers and genes/proteins. We identified 56 amino acid sites or “signatures” and 119 k-mers that differed between the vaccine and placebo groups. Of those, 19 sites and 38 k-mers were located in the regions comprising the RV144 vaccine (Env-gp120, Gag, and Pro). The nine signature sites in Env-gp120 were significantly enriched for known antibody-associated sites (p = 0.0021). In particular, site 317 in the third variable loop (V3) overlapped with a hotspot of antibody recognition, and sites 369 and 424 were linked to CD4 binding site neutralization. The identified signature sites significantly covaried with other sites across the genome (mean = 32.1) more than did non-signature sites (mean = 0.9) (p < 0.0001), suggesting functional and/or structural relevance of the signature sites. Since signature sites were not preferentially restricted to the vaccine immunogens and because most of the associations were insignificant following correction for multiple testing, we predict that few of the genetic differences are strongly linked to the RV144 vaccine-induced immune pressure. In addition to presenting results of the first complete-genome analysis of the breakthrough infections in the RV144 trial, this work describes a set of statistical methods and tools applicable to analysis of breakthrough infection genomes in general vaccine efficacy trials for diverse pathogens.

[1]  L. Ratner,et al.  Human Immunodeficiency Virus Type 1 Coreceptor Switching: V1/V2 Gain-of-Fitness Mutations Compensate for V3 Loss-of-Fitness Mutations , 2006, Journal of Virology.

[2]  Sergei L. Kosakovsky Pond,et al.  DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites. , 2010, BioTechniques.

[3]  W. Taylor,et al.  The classification of amino acid conservation. , 1986, Journal of theoretical biology.

[4]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[5]  Peter B Gilbert,et al.  Estimation of Stratified Mark-Specific Proportional Hazards Models with Missing Marks. , 2012, Scandinavian journal of statistics, theory and applications.

[6]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[7]  GottardoRaphael,et al.  Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial , 2014 .

[8]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[9]  S. Wold,et al.  Peptide quantitative structure-activity relationships, a multivariate approach. , 1987, Journal of medicinal chemistry.

[10]  P B Gilbert,et al.  Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. , 2000, Statistics in medicine.

[11]  Lynn Morris,et al.  Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.

[12]  Guido Ferrari,et al.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.

[13]  O. Gascuel,et al.  A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. , 2003, Systematic biology.

[14]  M. Nei,et al.  Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. , 1993, Molecular biology and evolution.

[15]  Paul T. Edlefsen.  Evaluating the dependence of a non-leaky intervention's partial efficacy on a categorical mark , 2012 .

[16]  Richard Routledge,et al.  Practicing safe statistics with the mid-p* , 1994 .

[17]  M Malkovsky,et al.  Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy. , 1992, Immunology.

[18]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[19]  E. Leifer,et al.  Multiple Outputation: Inference for Complex Clustered Data by Averaging Analyses from Independent Data , 2003, Biometrics.

[20]  Peter B. Gilbert,et al.  Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial , 2011, Nature Medicine.

[21]  Ming Li,et al.  Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies , 2010, PLoS Comput. Biol..

[22]  Jaranit Kaewkungwal,et al.  The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope , 2012, The Journal of Immunology.

[23]  A. Pinter,et al.  Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. , 1998, Vaccine.

[24]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[25]  Tomer Hertz,et al.  MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load , 2012, PloS one.

[26]  Gary J. Nabel,et al.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection , 2014, PloS one.

[27]  Noah G. Hoffman,et al.  Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop , 2002, Journal of Virology.

[28]  Raphael Gottardo,et al.  Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial , 2014, Journal of Virology.

[29]  Peter B Gilbert,et al.  Covariability of selected amino acid positions for HIV type 1 subtypes C and B. , 2005, AIDS research and human retroviruses.

[30]  S. Wold,et al.  New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. , 1998, Journal of medicinal chemistry.

[31]  John F. B. Mitchell,et al.  Quantifying the uncertainty in forecasts of anthropogenic climate change , 2000, Nature.

[32]  Morten Nielsen,et al.  MHC Class II epitope predictive algorithms , 2010, Immunology.

[33]  Tomer Hertz,et al.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2 , 2012, Nature.

[34]  Hasan Ahmed,et al.  Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials , 2012, The Journal of infectious diseases.

[35]  John P. Moore,et al.  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[36]  Pamela Warner,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand , 2010, Journal of Family Planning and Reproductive Health Care.

[37]  Bette Korber,et al.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.

[38]  Peter F Stadler,et al.  Modeling amino acid substitution patterns in orthologous and paralogous genes. , 2007, Molecular phylogenetics and evolution.

[39]  Punnee Pitisuttithum,et al.  Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. , 2004, The Journal of infectious diseases.

[40]  Peter B Gilbert,et al.  Genome scanning tests for comparing amino acid sequences between groups. , 2008, Biometrics.

[41]  A MarioCalvo,et al.  Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .

[42]  Ora Schueler-Furman,et al.  Learning MHC I - peptide binding , 2006, ISMB.

[43]  Allen Chen,et al.  High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV type 1 infections from a Phase 3 vaccine efficacy trial. , 2006, AIDS research and human retroviruses.

[44]  Feng Gao,et al.  Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals , 2011, Journal of Virology.

[45]  O. Lund,et al.  NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.

[46]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[47]  Raphael Gottardo,et al.  A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. , 2013, Journal of immunological methods.

[48]  David C. Nickle,et al.  HIV-Specific Probabilistic Models of Protein Evolution , 2007, PloS one.

[49]  Raphael Gottardo,et al.  Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial , 2013, PloS one.

[50]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[51]  S. Wold,et al.  DNA and peptide sequences and chemical processes multivariately modelled by principal component analysis and partial least-squares projections to latent structures , 1993 .

[52]  S. Henikoff,et al.  Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[54]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[55]  Alternate members,et al.  The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise , 2010, Nature Medicine.

[56]  Brian T. Foley,et al.  HIV-1 Subtype and Circulating Recombinant Form (CRF) Reference Sequences, 2005 , 2005 .

[57]  P B Gilbert,et al.  Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. , 1998, Biometrics.

[58]  Alessandro Sette,et al.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia , 2000, Nature.

[59]  Louis J. Picker,et al.  HIV-1 Vaccines and Adaptive Trial Designs , 2011, Science Translational Medicine.